A Multicenter Randomized Trial to Evaluate the Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients (CAMOVID)

Boutboul et al., NCT04608266, CAMOVID, NCT04608266, Dec 2021

TMPRSS2 inhibitors for COVID-19

19th treatment shown to reduce risk in April 2021, now with p = 0.00063 from 29 studies.
Lower risk for mortality, ventilation, and recovery.

No treatment is 100% effective.
Protocols combine treatments.

70 patient TMPRSS2 inhibitor early treatment RCT with results not reported over 4 years after completion.
7 TMPRSS2 inhibitors RCTs have results missing long after expected1-7
The trials report a total of 1,116 patients, with 3 trials having actual enrollment of 142, and the remainder estimated.
Study covers TMPRSS2 inhibitors and camostat.
Boutboul et al., 2 Dec 2021, Double Blind Randomized Controlled Trial, placebo-controlled, France, trial NCT04608266 (history) (CAMOVID). Contact: david.boutboul@aphp.fr.